Another trial, the open-label, single-center, phase II NeoTEE study, similarly showed the efficacy of Tucidinostat plus Exemestane in treating patients with HR+/HER2-, stage II/III breast cancer [93]. Here, ERBB2 is linked to breast carcinoma.